|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Lenvatinib
|
|
gptkbp:activities
|
tyrosine kinase inhibitor
|
|
gptkbp:approves
|
gptkb:2015
gptkb:FDA
|
|
gptkbp:clinical_trial
|
NC T02041260
NC T01728665
NC T01941424
NC T02811811
|
|
gptkbp:dosage_form
|
10 mg, 14 mg, 24 mg
|
|
gptkbp:form
|
gptkb:beer
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lenvima
|
|
gptkbp:ingredients
|
C22 H22 Cl N7 O4 S
lenvatinib
|
|
gptkbp:is_atype_of
|
L01 X E34
|
|
gptkbp:is_used_for
|
treatment of thyroid cancer
treatment of hepatocellular carcinoma
treatment of renal cell carcinoma
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Eisai_Co.,_Ltd.
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Japan
gptkb:United_States
|
|
gptkbp:side_effect
|
fatigue
nausea
hypertension
weight loss
vomiting
decreased appetite
diarrhea
proteinuria
stomatitis
|
|
gptkbp:targets
|
gptkb:FGFR
gptkb:KRAS
gptkb:VEGFR
gptkb:PDGFR
gptkb:BRAF
SRC
HGF
NRAS
KIT
MET
RET
VEGF
FGF
AXL
CS F1 R
ERB B2
ERB B3
ERB B4
IG F1 R
TI E2
|
|
gptkbp:weight
|
426.96 g/mol
|